Reinventing Neurodegenerative Protocols To Overcome COVID-19 Hurdles

The Case

A global, pivotal Phase III Alzheimer’s trial aiming to screen 6,000+ patients faced unforeseen challenges when the COVID-19 pandemic hit just a few months into recruitment.

The Solution

Proactive screening, assessment, and IP administration techniques enabled a new approach to collecting patient data and administering required IP and study visits. This preserved study integrity and enabled a resurgence in screening and recruitment to near-target levels within 8 weeks of the
pandemic beginning.

The sponsor has since awarded business on additional products to Worldwide Clinical Trials as a direct result of our nimble and adaptive response to challenging circumstances.